Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jecure Therapeutics
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
Business development execs Patrick Schleck and Michael Crowley talk to Scrip about the company’s recent deals with Parvus, Jecure and Microbiotica in the inflammatory and autoimmune disease space.